Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - propranolol hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: carmellose calcium; carmine; magnesium stearate; gelatin; hypromellose; glycerol; titanium dioxide; lactose monohydrate - indications as at 05 mar 02 : 1. angina pectoris, 2. hypertension, 3. prevention of migraine, 4. cardiac dysrhythmias : certain intrinsic cardiac dysrhythmias; dysrhythmias associated with thyrotoxicosis; anxiety tachycardia; certain drug-induced dysrhythmias (e.g. tachycardia due to digitalis or adrenaline overdosage), 5. essential tremor, including familial and senile tremor, 6.phaeochromocytoma (only with concurrent alpha-receptor blockade), 7. hypertrophic subaortic stenosis, 8. suspected or definite myocardial infarction, 9. fallot's tetralogy.

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 60 mg - inderal la is indicated in the management of hypertension. it may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. inderal la is not indicated in the management of hypertensive emergencies. inderal la is indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. inderal la is indicated for the prophylaxis of common migraine headache. the efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. inderal la improves nyha functional class in symptomatic patients with hypertrophic subaortic stenosis. propranolol is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first-degree block; 3) bronchial asthma; and 4) in patients with known hypersensitivity to propranolol hydrochloride.

United States - English - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 80 mg - inderal xl is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. inderal xl is contraindicated in patients with: risk summary prolonged experience with propranolol in pregnant women over several decades, based on published interventional and observational studies, has not identified a drug associated risk of major birth defects, miscarriage, or other adverse maternal outcomes. bradycardia, hypoglycemia, and respiratory depression have been observed with use of beta-blockers, including propranolol, in utero near the time of delivery. there are inconsistent reports of intrauterine growth restriction with beta-blocker use, including propranolol, during pregnancy. untreated hypertension during pregnancy can lead to serious adverse outcomes for the mother and the fetus (see clinical considerations and data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage) hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. pregnant women with hypertension should be carefully monitored and managed accordingly. fetal/neonatal adverse reactions propranolol crosses the placenta. neonates born to mothers who are receiving propranolol during pregnancy, may be at risk for bradycardia, hypoglycemia, and respiratory depression. monitor neonates exposed to propranolol during pregnancy and manage accordingly. data animal data in a series of reproductive and developmental toxicology studies, propranolol was given to rats by gavage or in the diet throughout pregnancy and lactation. at doses of 150 mg/kg/day, but not at doses of 80 mg/kg/day (equivalent to the maximum recommended human oral daily dose (mrhd) on a body surface area basis), treatment was associated with embryotoxicity (reduced litter size and increased resorption rates) as well as neonatal toxicity (deaths). propranolol hcl was also administered (in the feed) to rabbits (throughout pregnancy and lactation) at doses as high as 150 mg/kg/day (about 5 times the mrhd). no evidence of embryo or neonatal toxicity was noted. risk summary propranolol is present in human milk at low levels, but the related risk to a breastfed infant is unknown. there are no data on the effects of propranolol on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for inderal xl and any potential adverse effects on the breastfed child from inderal xl or from the underlying maternal condition. infertility males based on the published literature, beta-blockers, including propranolol, may cause erectile dysfunction. in rats, propranolol inhibits spermatogenesis [see nonclinical toxicology (13.1)] . safety and effectiveness of propranolol in pediatric patients have not been established. clinical studies of inderal xl did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. the exposure to propranolol is increased in patients with renal impairment. initiate inderal xl therapy in patients with impaired renal function at the lowest dose (80 mg) once daily and monitor patients for marked bradycardia and hypotension [see clinical pharmacology (12.6)] . the exposure to propranolol is increased in patients with hepatic impairment. initiate inderal xl therapy in patients with impaired hepatic function at the lowest dose (80 mg) once daily and monitor patients for marked bradycardia and hypotension [see clinical pharmacology (12.6)] .

United States - English - NLM (National Library of Medicine)

mist pharmaceuticals, llc - propranolol hydrochloride (unii: f8a3652h1v) (propranolol - unii:9y8nxq24vq) - propranolol hydrochloride 80 mg - inderal® xl is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different m

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - propranolol hydrochloride 160mg - modified release capsule - 160 mg - active: propranolol hydrochloride 160mg excipient: erythrosine ethylcellulose gelatin hypromellose iron oxide black iron oxide red microcrystalline cellulose titanium dioxide

Canada - English - Health Canada

ayerst laboratories - propranolol hydrochloride - capsule (sustained-release) - 160mg - propranolol hydrochloride 160mg - beta-adrenergic blocking agents

Canada - English - Health Canada

ayerst laboratories - propranolol hydrochloride - capsule (sustained-release) - 80mg - propranolol hydrochloride 80mg - beta-adrenergic blocking agents

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - propranolol hydrochloride -

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - propranolol hydrochloride - prolonged release capsules - 80

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - propranolol hydrochloride - prolonged release capsules - 80